# OnCo record solu-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/solu-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "solu-therapeutics" ;
  schema:name "Solu Therapeutics"@en ;
  schema:description "Solu Therapeutics makes molecules that mark disease-driving cells for destruction by the immune system. Its lead, STX-0712, targets the abnormal monocytes of chronic myelomonocytic leukaemia and is in an early trial that has added acute myeloid leukaemia."@en ;
  schema:url <https://onco.cc/companies/solu-therapeutics/>, <https://solutherapeutics.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://solutherapeutics.com/>, <https://cdn.prod.website-files.com/669551ccc7908830b842dc2b/67f55ddc890a926ab1f047c9_Final%20Solu%20press%20release_4.9.pdf>, <https://clinicaltrials.gov/study/NCT06950034> ;
  schema:addressCountry "US" ;
  onco:related <https://onco.cc/companies/solve-therapeutics/> ;
  onco:cancers <https://onco.cc/cancers/cmml/>, <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> .